---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-26-000019"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-08-28T20:06:46+00:00"
generated_at: "2026-08-28T20:08:10.341419+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics to acquire ST-920 gene therapy for Fabry disease from Sangamo for $111M upfront

## Summary
- Upfront $111M plus up to $100M milestones: $80M on FDA accelerated approval, $20M on full approval of ST-920 BLA.
- ST-920 is a one-time AAV gene therapy candidate for Fabry disease, acquired from Sangamo in bankruptcy auction.
- Closing subject to Bankruptcy Court approval (hearing Sept 10, 2026) and HSR waiting period; deadline Oct 15, 2026.
- PTC was selected as winning bidder in Sangamo's Chapter 11 case; agreement includes customary reps/warranties, no indemnification.

## SEC filing metadata
- accession: 0001070081-26-000019
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-08-28T20:06:46+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/0001070081-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/tmb-20260825x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-26-000019
- JSON: https://secwatch.observer/filing/0001070081-26-000019.json
- Plain text: https://secwatch.observer/filing/0001070081-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.